Chang H. Ahn
Chief Executive Officer – Founder and Chairman
Dr. Chang H. Ahn is an internationally recognized drug development expert with over 20 years of experience in the fields of pharmacology and biotechnology. He founded Rexahn in 2001, and currently serves as the company’s Chairman and Chief Executive Officer. Prior, Dr. Ahn held dual positions as both Expert Regulatory Officer and Laboratory Chief at the FDA’s Center for Drug Evaluation and Research. While at the FDA, Dr. Ahn represented the agency in the fields of Antisense Oligonucleotide Therapeutics and Multi-Drug Resistance, and served a key role as both author and co-author of several FDA guidance documents. Before joining the FDA, Dr. Ahn carried out cancer research at the National Cancer Institute and Emory University’s School of Medicine. Dr. Ahn organized and chaired the U.S.-Korea Bio Business and Partnership Forum, of which Maryland State and Montgomery County are partners. He has also served as president of the Society of Biomedical Research since 2000.
Charles Beever
Director
Mr. Beever has served as a director since May 2006. He is currently a partner and Vice President of Booz & Company. He was a partner and Vice President of Booz Allen & Hamilton, Inc. from 1993 to 2009, and served as staff member and Engagement Manager at Booz Allen Hamilton from January 1984 to October 2003. Prior to joining Booz Allen Hamilton, Mr. Beever served as Plant Production Manager from October 1981 to January 1984, Industrial Engineering Manager from June 1979 to October 1981 and Production Supervisor from July 1978 to June 1979 at McGraw-Edison Company. Mr. Beever holds a B.A. in Economics from Haverford College, where he was elected to Phi Beta Kappa, and an M.B.A. from the Harvard Graduate School of Business Administration.
Peter Brandt
Director
Mr. Brandt has served as a director since September 2010. He was most recently President and Chief Executive Officer of Noven Pharmaceuticals. Prior to leading Noven, Brandt spent 28 years at Pfizer, the world’s largest pharmaceutical company. He served as Pfizer’s President – U.S. Pharmaceuticals Operations, where he helped deliver revenue and earnings growth while engineering major change within Pfizer’s U.S. pharmaceuticals organization. Prior to running the U.S. operations, he led the Latin American Pharmaceuticals Operations, as well as the following Pfizer Worldwide Pharmaceuticals functions: Finance, Information Technology, Planning and Business Development. He also oversaw the operations of Pfizer’s care management subsidiary, Pfizer Healthcare Solutions. Mr. Brandt holds a BA from the University of Connecticut and an MBA from the Columbia School of Business.
Kwang Soo Cheong
Director
Dr. Cheong has served as a director since May 2006. He is a faculty member at the Department of Finance of the Johns Hopkins University Carey Business School (Assistant Professor: 2001-2005 & Associate Professor: 2006 to date). Dr. Cheong was an Assistant Professor of Economics at the University of Hawaii from 1994 to 2001, and he was a lecturer at the Department of Economics of Stanford University from 1993 to 1994. During the summer of 1995, Dr. Cheong was a Visiting Fellow in the Taxation and Welfare Division at the Korea Development Institute in Korea. Dr. Cheong holds a B.A. in Economics and an M.A. in Economics from Seoul National University, and a Ph.D. in Economics from Stanford University.
Tae Heum (Ted) Jeong
Director and Secretary
Mr. Jeong joined Rexahn Pharmaceuticals in 2002 and has served as a director since May 2005. He has extensive experience as a venture capitalist. Prior to joining Rexahn, Mr. Jeong spent six years as a senior investment manager at Hyundai Venture Investment Corporation, the leading Korean venture capital firm. At Hyundai, he managed the biotech investment team, and operated two specialized biotechnology funds. He also held the position of Committee Member with the Industrial Development Fund of the Korean Ministry of Commerce, Industry and Energy. After joining Rexahn, Mr. Jeong’s accomplishments include securing public market listings, mergers, and successful fundraising efforts. Mr. Jeong holds a M.S. in Finance from Johns Hopkins University, a B.S. in Chemistry and an M.S., specializing in Biomedical Chemistry, from POSTECH, Pohang, Korea.
Richard Paul Kivel
Director
Mr. Kivel has served as a director since September 2010. He presently serves as Chairman of Rhapsody Biologics, a biotech company focused in the field of vaccine development, with offices in the US and Singapore. Prior to this, he served as CEO of TheraGenetics, a UK-based genetic diagnostics company developing pharmacogenetic tests to improve the treatment of Central Nervous System (CNS) disorders. TheraGenetics was acquired by UK based Avacta Group plc. (LSE: AVCT). He also serves as Chairman of the global Board of Directors of the MIT Enterprise Forum and is a member of the MIT Alumni Association Board. Additionally, he is a member of the Board of Trustees of Fundación de la Innovación Bankinter in Madrid, Spain. Mr. Kivel holds a B.A degree from American International College, an M.S in management from Boston College, and is a graduate of University of Pennsylvania Executive Program: Drug Discovery, Therapeutics & New Innovations.
David McIntosh
Director
Mr. McIntosh has served as a director since May 2005. Mr. McIntosh served as a director of Rexahn, Corp from March 2004 to May 2005. He has been a partner at the law firm, Mayer Brown LLP, since 2001. Mr. McIntosh was a member of the United States House of Representatives, representing the 2nd District of Indiana from 1995 to 2001. From 1993 to 1994, he was a director of the Hudson Institute Competitiveness Center. He served on President Bush’s Council on Competitiveness as Executive Director from 1989 to 1993. He also served as the Special Assistant to President Reagan for Domestic Affairs from 1987 to 1989 and was the Special Assistant to the Attorney General of the United States from 1986 to 1987. Mr. McIntosh received a B.A. from Yale College and a J.D. from the University of Chicago Law School.